Good, now I have solid data. Let me also check for any recent M&A news or 8-K filings in the interim period.# IEX (IDEX Corporation) Q2 2026 Earnings Preview
Report Date: Wednesday, July 29, 2026, before market open | Call at 9:00 AM ET
IDEX Corporation heads into its second-quarter 2026 report riding significant momentum. The stock has been one of the stronger performers in the industrial space this year — IEX stock has climbed 22.7% in 2026, leaving the benchmark index's 9.3% year-to-date gain in the rearview mirror, and it has also turned the tables on its own sector, comfortably ahead of the Industrial Select Sector SPDR ETF's 16.3% YTD advance. Much of that outperformance traces back to the Q1 report on April 29, when IDEX stock climbed 5.8% intraday following its Q1 FY2026 earnings release — a beat-and-raise quarter that reset expectations higher for the rest of the year.
Q1 was a clean beat across the board. IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, reflecting margin expansion of 50 basis points year-over-year, with results above expectations across each segment. The standout was orders, up ~10% organically, with Health & Science Technologies (HST) posting organic order growth of 17% year-over-year, driven by secular demand in data centers, semiconductors, and space/defense. Revenue of $887 million (+9% reported, +5% organic) beat the Street's $847.4 million estimate, and adjusted EPS of $2.00 beat consensus of $1.78 by $0.22, with the industrial products company reporting a return on equity of 15.29% and a net margin of 14.38%.
That strength prompted management to raise full-year guidance meaningfully: full-year organic sales growth was lifted to 3%–4% (from 1%–2%), and adjusted diluted EPS guidance rose to $8.35–$8.55 (from $8.15–$8.35). For Q2 specifically, management guided to 3%–4% organic growth and adjusted EPS of $2.07–$2.12.
HST (Health & Science Technologies) — the growth engine. HST organic orders increased 17% and organic sales grew 11% in Q1, fueled by AI-driven demand for data center power, semiconductor manufacturing/optical switching, and space & defense, while life sciences remained a soft spot due to China end-market pressure and NIH/academic funding headwinds. Management noted a continuing strong backlog build in HST, giving them visibility to "high single-digit to double-digit growth" through the balance of 2026. HST margins expanded 100bps in Q1, but incremental margins (~33%, "low to mid-30s") remain below the historical 40%+ target, gated by newer acquisitions (Mott, Muon, Micro-LAM) still ramping toward segment-average profitability and a life-sciences recovery that hasn't yet materialized.
FMT (Fluid & Metering Technologies) — inflecting but guided conservatively. FMT orders grew 9% organically in Q1 on strength in water/municipal, pumps, and mining, while chemical and general industrial end markets stayed soft. Management characterized the short-cycle industrial recovery as "mixed" — weak in January, improving through February/March, and holding at that level into April — while keeping full-year guidance for FMT roughly flat, citing lingering geopolitical uncertainty and a preference not to extrapolate one strong quarter.
FSDP (Fire & Safety/Diversified Products) — stabilizing. FSDP orders declined 4% in Q1 with Fire & Safety growing high-single digits (especially North America) offset by weakness in Dispensing tied to project timing. Investors should watch for confirmation that Dispensing has stabilized sequentially, as management indicated it expected in Q1.
Wall Street expects IDEX to deliver diluted EPS of $2.11, marking a 1.93% increase from $2.07 in the same quarter last year, with revenue expectations of $905.375 million for the quarter — squarely within/near the top of management's own $2.07–$2.12 EPS guidance range. Notably, the bar looks achievable: IDEX has comfortably cleared analysts' earnings estimates in each of the past four quarters.
Second-half organic growth trajectory. On the Q1 call, analysts pushed management on why growth would decelerate from Q1's 5% pace to the 3–4% full-year guide. CFO Sean Gillen explained that HST should sustain high-single to double-digit growth on backlog, but FMT/FSDP were being modeled conservatively flat given still-uncertain short-cycle industrial demand and only one quarter of data. Watch for whether Q2 order trends (especially the sequential improvement seen from January through April) continued into May/June, which could set up another raise.
AI/data-center and semiconductor exposure — a double-edged sword. IDEX's HST growth is heavily levered to AI infrastructure buildout (data center power, semiconductor equipment/consumables, optical switching). This has been a tailwind, but recent volatility in semiconductor-related equities — including sharp declines in SK Hynix and ASML on China competition concerns, even as peers like Teradyne posted blowout AI-driven results — suggests investors will be listening closely for any commentary on order durability versus mismatch/pull-forward risk in these advantaged end markets.
HST margin recovery path. Management has guided to "mid-30s" incremental margins in HST for 2026, working toward a 40%+ historical target as acquired businesses (Mott, Muon, Micro-LAM) mature under the "8020" operating playbook and life sciences recovers. Any update on the pace of this margin build — or on life sciences finally inflecting — would be a positive catalyst.
Capital deployment. IDEX repurchased $76 million of shares in Q1 and reiterated intent to maintain that quarterly pace through 2026, alongside an active bolt-on M&A pipeline, while maintaining leverage around 2x gross debt/EBITDA and liquidity of roughly $1.1 billion. Watch for confirmation of continued buyback pace and any new tuck-in deal announcements.
Tariffs. Management noted that new tariffs implemented after the repeal of IEEPA tariffs are largely consistent with what was repealed, such that they don't anticipate much net financial impact, and the company has applied for IEEPA refunds. Any change in this dynamic, or in price/cost trends (positive in Q1), is worth monitoring.
Wall Street currently gives the stock an overall "Moderate Buy" rating, with the average price target of $240.36 implying potential upside of roughly 10% from current levels, and a Street-high target of $260. In the weeks following Q1 earnings, several sell-side firms raised targets: Stifel Nicolaus boosted its price objective to $257 with a Buy rating, TD Cowen raised its target to $260, Citigroup lifted its target to $252, and Oppenheimer raised its target to $260 with an Outperform rating — signaling broad sell-side conviction that the growth/margin story has legs heading into Q2.
IEX enters this print with a high bar of its own making after four consecutive quarters of beats and a meaningfully raised full-year outlook. The setup favors continued strength in HST (AI, semiconductors, space/defense, data centers), with the swing factors being (1) whether FMT/FSDP's tentative short-cycle industrial recovery continues to firm up, (2) whether HST margins/incremental flow-through show further progress, and (3) whether management raises full-year guidance again or reiterates the current $8.35–$8.55 EPS range. Given the stock's strong run-up into the print, the market's reaction may hinge less on an EPS beat (which appears largely expected) and more on the tone of forward commentary on order momentum and second-half visibility.